United Therapeutics Corporation develops and commercializes an array of specialized pharmaceutical products targeting severe cardiovascular and oncological conditions. Its core commercial medicine portfolio includes Remodulin, Tyvaso, Tyvaso DPI, Orenitram, Adcirca, and Unituxin. These therapies are primarily prescribed for pulmonary arterial hypertension and high-unmet-need specialty oncology indications, supported by an active clinical research pipeline.